We are live on
!
Find out more
MAM
MPM Asset Management Portfolio holdings
AUM
$44.5M
1-Year Est. Return
47.28%
This Fund
S&P 500
This Quarter
Est. Return
-15.41%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$43.3M
AUM Growth
-$26.1M
(-38%)
Cap. Flow
-$16.5M
Cap. Flow
% of AUM
-38.04%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITOS
iTeos Therapeutics
ITOS
|
+$16.4M |
| 2 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$140K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
WCPI
BAM
WAMC
NLVP
CIEP
IPI
CC
VSAM
MPM Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, MPM Asset Management held 6 positions worth $43.3M, down 38% from $69.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
MPM Asset Management withdrew a net $16.5M in Q2 2025, closing 1 position and reducing 1 holding. Its most notable exit was iTeos Therapeutics, an estimated $16.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- MPM Asset Management's biggest Q2 2025 reduction was Adaptimmune Therapeutics, cutting an estimated $140K.
- MPM Asset Management fully exited iTeos Therapeutics in Q2 2025, selling an estimated $16.4M.
- MPM Asset Management's ten largest holdings make up 100% of its $43.3M portfolio in Q2 2025.
- MPM Asset Management opened 0 new positions and closed 1 in Q2 2025.
- MPM Asset Management's portfolio value fell 38% quarter-over-quarter to $43.3M.
Based on MPM Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.